Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer .
研究概览
地位
干预/治疗
- 生物:anti-thymocyte globulin
- 药品:fludarabine phosphate
- 药品:melphalan
- 药品:methotrexate
- 药品:sirolimus
- 药品:tacrolimus
- 程序:allogeneic hematopoietic stem cell transplantation
- 程序:hematopoietic stem cell transplantation
- 程序:nonmyeloablative allogeneic hematopoietic stem cell transplantation
- 程序:peripheral blood stem cell transplantation
- 辐射:total-body irradiation
- 药品:cyclophosphamide
- 药品:etoposide
详细说明
OBJECTIVES:
Primary
- To determine the incidence and severity of acute- and chronic-graft-versus-host disease (GVHD) after HLA-matched or -mismatched unrelated donor hematopoietic peripheral blood transplantation in patients with hematologic malignancies scheduled to receive immunosuppressive combination of sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD prophylaxis.
- To determine the safety of this combination in the first six months post-transplant.
Secondary
- To determine the time-to-engraftment, non-relapse mortality rate, overall and disease-free survival, incidence of disease relapse, and incidence of opportunistic infections with this GVHD prophylaxis.
OUTLINE: Patients are stratified according to conditioning regimen (fludarabine phosphate and melphalan vs fractionated total-body irradiation [FTBI] and etoposide vs FTBI and cyclophosphamide) and degree of donor/recipient HLA mismatch (high-risk vs low-risk).
- Conditioning regimen: Patients receive 1 of 3 standard conditioning regimens beginning on day -9 or -8 and continuing to day -1 or 0.
- Peripheral blood stem cell transplantation: Patients receive HLA-matched or mismatched unrelated donor peripheral blood stem cells on day 0.
- Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -3 and then orally when tolerated, oral sirolimus on days -3 and -2, anti-thymocyte globulin IV over 4-8 hours on days -3 to 0, and methotrexate* IV on days 1, 3, and 6. Tacrolimus and sirolimus continue for 3-6 months (with taper).
NOTE: *Only patients with high-risk HLA mismatch receive treatment with methotrexate.
After completion of study therapy, patients are followed periodically for up to 2 years.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- Banner Good Samaritan Medical Center
-
-
California
-
Duarte、California、美国、91010-3000
- City of Hope Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Diagnosis of hematological malignancy including any of the following:
- Non-Hodgkin lymphoma (NHL) in any complete remission (CR) or partial response (PR)
- Hodgkin lymphoma in any CR or PR
Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in any CR
- Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation of conditioning for patients with non-CR AML or ALL
- Myelodysplastic syndromes (MDS) treated or untreated
- Chronic myelogenous leukemia (CML) in chronic or accelerated phase
- Multiple myeloma in any CR or PR
- Chronic lymphocytic leukemia in CR or PR 2 or greater
Myelofibrosis and other myeloproliferative disorders
- Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation
- High-risk disease defined as AML or ALL > CR1, accelerated phase CML, recurrent aggressive lymphoma, or active lymphoproliferative disease at transplant
- Low-risk disease defined as AML or ALL in CR1, chronic phase CML, or low-grade lymphoproliferative disorder with controlled disease at transplant
Must be planning to receive 1 of the following conditioning regimens at City of Hope:
- Fludarabine phosphate and melphalan for patients with hematological malignancies and contraindications for conventional myeloablative regimens due to age, co-morbidity, or previous transplant
- Fractionated total-body irradiation (FTBI) and etoposide for patients with AML and ALL or CML in accelerated phase
- FTBI and cyclophosphamide for patients with NHL, AML, CML, and MDS
Suitable unrelated donor available
- HLA-matched or mismatched
- Peripheral blood stem cells available
- No bone marrow or ex vivo-engineered or processed graft (e.g., CD34-positive, T-cell depletion)
- No uncontrolled CNS disease
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 70-100% or ECOG PS 0-2
- Creatinine < 1.3 mg/dL or creatinine clearance ≥ 70 mL/min
- Ejection fraction > 45%
- Direct bilirubin < 3 times upper limit of normal (ULN)
- ALT and AST < 3 times ULN
- Forced vital capacity, FEV1, and DLCO > 45% of predicted
- Able to cooperate with oral medication intake
- No active donor or recipient serology positive for HIV
- No known contraindication to administration of sirolimus, tacrolimus, or anti-thymocyte globulin
- No active hepatitis B or C
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Concurrent participation in other clinical trials for prevention or treatment of viral, bacterial, or fungal disease allowed provided agents do not interact with agents used in the current study
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Fludarabine/Melphalan Conditioning
Fludarabine/Melphalan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis |
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
Melphalan 140 mg/m2 on day -4 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
|
实验性的:FTBI/Cytoxan Conditioning
FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
|
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
60mg/kg on days -5 and -4 from stem cell transplant
|
实验性的:FTBI/Etoposide Conditioning
FTBI/Etoposide Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis |
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
60mg/kg on day -4 from stem cell transplant
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100
大体时间:100 Days Post Hematopoietic Stem Cell Transplant (HSCT)
|
Patients were evaluated for the development of acute GVHD within the first 100 days post HSCT.
The cumulative incidence of grade II-IV acute GVHD was determined using competing risk analysis.
Competing risks for acute GVHD were death and nonengraftment.
|
100 Days Post Hematopoietic Stem Cell Transplant (HSCT)
|
Severity of Acute GVHD
大体时间:100 Days Post HSCT
|
All patients were considered for the evaluation of the severity of acute GVHD.
|
100 Days Post HSCT
|
Cumulative Incidence of Chronic GVHD
大体时间:2 year point estimate was provided.
|
Patients were evaluated for the development of chronic GVHD from 101 days post HSCT to last contact or documented evidence of the disease.
The cumulative incidence of chronic GVHD was determined using competing risk analysis.
Competing risks for GVHD were death and nonengraftment.
|
2 year point estimate was provided.
|
Severity of Chronic GVHD
大体时间:Patients were evaluated until they developed chronic GVHD, a median of 130 days post HSCT
|
All Patients were considered for the evaluation of chronic GVHD severity.
|
Patients were evaluated until they developed chronic GVHD, a median of 130 days post HSCT
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Time to Absolute Neutrophil Count Recovery (Engraftment)
大体时间:Patients were evaluated until neutrophil recovery, a median of 15 days post HSCT
|
Absolute neutrophil count (ANC) recovery is defined as an ANC of ≥ 0.5 x 10^9/L (500/mm3) for three consecutive laboratory values obtained on different days
|
Patients were evaluated until neutrophil recovery, a median of 15 days post HSCT
|
Time to Platelet Count Recovery (Engraftment)
大体时间:Patients were evaluated until platelet recovery, a median of 14 days
|
Platelet recovery is defined as the first date of three consecutive laboratory values ≥ 25 x 10^9 L obtained on different days.
|
Patients were evaluated until platelet recovery, a median of 14 days
|
Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation
大体时间:Median Follow Up: 28 months (Range: 1-49 months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
|
Median Follow Up: 28 months (Range: 1-49 months)
|
Occurrence of Thrombotic Microangiopathy
大体时间:Median Follow Up: 28 Months (Range: 1-49 months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
This is the number of participants who developed TMA.
|
Median Follow Up: 28 Months (Range: 1-49 months)
|
Occurence of Sinusoidal Obstructive Syndrome (SOS)
大体时间:Median Follow Up: 28 Months (Range: 1-49 Months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
This is the number of participants who developed SOS.
|
Median Follow Up: 28 Months (Range: 1-49 Months)
|
Non-relapse Mortality at 100 Days Post HSCT
大体时间:100 day point estimate was provided
|
Patients were evaluated for non-relapse mortality (NRM) throughout the study.
Non-relapse mortality was considered any death not attributable to relapse or disease progression.
The cumulative incidence of NRM was determined using competing risk analysis.
Competing risks for NRM were death due to disease progression, relapse and nonengraftment.
|
100 day point estimate was provided
|
Non-relapse Mortality at Two Years Post HSCT
大体时间:2 year point estimate was provided.
|
Patients were evaluated for non-relapse mortality (NRM) throughout the study.
Non-relapse mortality was considered any death not attributable to relapse or disease progression.
The cumulative incidence of NRM was determined using competing risk analysis.
Competing risks for NRM were death due to disease progression, relapse and nonengraftment.
|
2 year point estimate was provided.
|
Overall Survival at Two Years Post HSCT
大体时间:2 year point estimate was provided.
|
Patients were evaluated for survival (OS) throughout the study.
Kaplan Meier estiamtes were calculated for overall survival using time from HSCT to death of any cause or for surviving patients last contact date.
|
2 year point estimate was provided.
|
Event Free Survival at Two Years Post HSCT
大体时间:2 year point estimate was provided.
|
Patients were evaluated for event free survival (EFS) throughout the study.
Events were defined as death, relapse, progression, or nonengraftment.
Kaplan Meier estimates were calculated as time from HSCT to event.
|
2 year point estimate was provided.
|
Incidence of Disease Relapse/Progression at 2 Years Post HSCT
大体时间:2 year point estimate was provided.
|
Patients were evaluated for relapse/progression post transplant throughout the study.
The cumulative incidence of relapse/progression was determined using competing risk analysis.
Competing risks for relapse were non-relapse mortality and nonengraftment.
|
2 year point estimate was provided.
|
合作者和调查者
调查人员
- 学习椅:Ryotaro Nakamura, MD、City of Hope Comprehensive Cancer Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
- 原发性骨髓纤维化
- I期皮肤T细胞非霍奇金淋巴瘤
- I期慢性淋巴细胞白血病
- 感染
- III期成人弥漫性大细胞淋巴瘤
- III期成人免疫母细胞大细胞淋巴瘤
- III期成人伯基特淋巴瘤
- IV期3级滤泡性淋巴瘤
- IV期成人弥漫性大细胞淋巴瘤
- IV期成人免疫母细胞大细胞淋巴瘤
- IV期成人Burkitt淋巴瘤
- 复发性 3 级滤泡性淋巴瘤
- 复发性成人弥漫性大细胞淋巴瘤
- 复发性成人免疫母细胞大细胞淋巴瘤
- 复发性成人伯基特淋巴瘤
- III期儿童小无裂细胞淋巴瘤
- IV期儿童小无裂细胞淋巴瘤
- 复发性儿童小无裂细胞淋巴瘤
- 慢性粒单核细胞白血病
- 新生骨髓增生异常综合征
- 既往治疗过的骨髓增生异常综合征
- 继发性骨髓增生异常综合征
- 具有 11q23 (MLL) 异常的成人急性髓性白血病
- 伴有 inv(16)(p13;q22) 的成人急性髓性白血病
- 成人急性髓性白血病伴 t(15;17)(q22;q12)
- 成人急性髓性白血病伴 t(16;16)(p13;q22)
- 成人急性髓性白血病伴 t(8;21)(q22;q22)
- 继发性急性髓性白血病
- 儿童急性淋巴细胞白血病处于缓解期
- 儿童急性髓性白血病处于缓解期
- 幼年粒单核细胞白血病
- 慢性期慢性粒细胞白血病
- 儿童骨髓增生异常综合征
- 复发性成人急性髓性白血病
- 缓解期成人急性髓性白血病
- 复发性成人霍奇金淋巴瘤
- 复发/难治性儿童霍奇金淋巴瘤
- 复发性成人弥漫性小裂细胞淋巴瘤
- 复发性成人弥漫性混合细胞淋巴瘤
- 复发性慢性粒细胞白血病
- III 期 1 级滤泡性淋巴瘤
- III期2级滤泡性淋巴瘤
- III期3级滤泡性淋巴瘤
- III期成人弥漫性小裂细胞淋巴瘤
- III期成人弥漫性混合细胞淋巴瘤
- IV 期 1 级滤泡性淋巴瘤
- IV 期 2 级滤泡性淋巴瘤
- IV期成人弥漫性小裂细胞淋巴瘤
- IV期成人弥漫性混合细胞淋巴瘤
- III期套细胞淋巴瘤
- IV期套细胞淋巴瘤
- II期多发性骨髓瘤
- III期多发性骨髓瘤
- I期成人弥漫性小裂细胞淋巴瘤
- 复发性 1 级滤泡性淋巴瘤
- 复发性 2 级滤泡性淋巴瘤
- 连续 II 期 1 级滤泡性淋巴瘤
- 连续 II 期 2 级滤泡性淋巴瘤
- 连续 II 期成人弥漫性小裂细胞淋巴瘤
- 非连续性 II 期 1 级滤泡性淋巴瘤
- 非连续性 II 期 2 级滤泡性淋巴瘤
- 非连续性 II 期成人弥漫性小裂细胞淋巴瘤
- 非连续性 II 期小淋巴细胞淋巴瘤
- 非连续性 II 期边缘区淋巴瘤
- 复发性边缘区淋巴瘤
- 复发性小淋巴细胞淋巴瘤
- III期小淋巴细胞淋巴瘤
- III期边缘区淋巴瘤
- IV期小淋巴细胞淋巴瘤
- IV期边缘区淋巴瘤
- 连续II期边缘区淋巴瘤
- 相邻的 II 期小淋巴细胞淋巴瘤
- 黏膜相关淋巴组织结外边缘区B细胞淋巴瘤
- 淋巴结边缘区B细胞淋巴瘤
- 脾边缘区淋巴瘤
- I期多发性骨髓瘤
- 复发性成人淋巴母细胞淋巴瘤
- 复发性套细胞淋巴瘤
- 难治性慢性淋巴细胞白血病
- II期慢性淋巴细胞白血病
- III期慢性淋巴细胞白血病
- IV期慢性淋巴细胞白血病
- III期成人霍奇金淋巴瘤
- IV期成人霍奇金淋巴瘤
- III期皮肤T细胞非霍奇金淋巴瘤
- IV 期皮肤 T 细胞非霍奇金淋巴瘤
- 复发性皮肤 T 细胞非霍奇金淋巴瘤
- 小肠淋巴瘤
- III期成人淋巴母细胞淋巴瘤
- IV期成人淋巴母细胞淋巴瘤
- III期成人T细胞白血病/淋巴瘤
- IV 期成人 T 细胞白血病/淋巴瘤
- 复发性成人 T 细胞白血病/淋巴瘤
- 血管免疫母细胞性T细胞淋巴瘤
- 间变性大细胞淋巴瘤
- 复发性成人 III 级淋巴瘤样肉芽肿病
- 皮肤B细胞非霍奇金淋巴瘤
- 复发性成人急性淋巴细胞白血病
- 复发性儿童急性淋巴细胞白血病
- III期儿童淋巴母细胞淋巴瘤
- IV期儿童淋巴母细胞淋巴瘤
- 连续II期套细胞淋巴瘤
- 非连续性 II 期套细胞淋巴瘤
- II期皮肤T细胞非霍奇金淋巴瘤
- 非连续性 II 期成人弥漫性大细胞淋巴瘤
- 非连续性 II 期成人弥漫性混合细胞淋巴瘤
- 非连续性 II 期成人淋巴母细胞淋巴瘤
- 非连续性 II 期 3 级滤泡性淋巴瘤
- 加速期慢性粒细胞白血病
- 缓解期成人急性淋巴细胞白血病
- IV期儿童霍奇金淋巴瘤
- 复发性儿童急性髓性白血病
- 骨髓增生异常/骨髓增生性肿瘤,无法分类
- 非典型慢性粒细胞白血病,BCR-ABL 阴性
- 非连续性 II 期成人伯基特淋巴瘤
- 非连续性 II 期成人免疫母细胞大细胞淋巴瘤
- 复发性儿童淋巴母细胞淋巴瘤
- III期儿童霍奇金淋巴瘤
- I期成人霍奇金淋巴瘤
- II期成人霍奇金淋巴瘤
- I期成人伯基特淋巴瘤
- 连续 II 期成人伯基特淋巴瘤
- 连续 II 期成人免疫母细胞大细胞淋巴瘤
- I期成人免疫母细胞大细胞淋巴瘤
- I期儿童霍奇金淋巴瘤
- II期儿童霍奇金淋巴瘤
- 复发性儿童 III 级淋巴瘤样肉芽肿病
- 复发性儿童间变性大细胞淋巴瘤
- III期儿童间变性大细胞淋巴瘤
- IV期儿童间变性大细胞淋巴瘤
- 连续 II 期 3 级滤泡性淋巴瘤
- 连续 II 期成人弥漫性大细胞淋巴瘤
- 连续II期成人弥漫性混合细胞淋巴瘤
- I期成人弥漫性大细胞淋巴瘤
- I期成人弥漫性混合细胞淋巴瘤
- I期成人T细胞白血病/淋巴瘤
- 连续 II 期成人淋巴母细胞淋巴瘤
- I期成人淋巴母细胞淋巴瘤
- 伯基特淋巴瘤
- 移植物抗宿主病
- 成人霍奇金淋巴瘤预后良好
- 成人不良预后霍奇金淋巴瘤
- 继发性骨髓纤维化
- 儿童霍奇金淋巴瘤预后不良
- childhood favorable prognosis Hodgkin lymphoma
- 复发性 I 级淋巴瘤样肉芽肿病
- 复发性 II 级淋巴瘤样肉芽肿病
其他相关的 MeSH 术语
- 消化系统疾病
- 病理过程
- 心血管疾病
- 血管疾病
- 免疫系统疾病
- 组织学类型的肿瘤
- 淋巴增生性疾病
- 淋巴系统疾病
- 免疫增生性疾病
- 按部位分类的肿瘤
- 疾病
- 骨髓疾病
- 血液病
- 消化道肿瘤
- 消化系统肿瘤
- 肠胃疾病
- 出血性疾病
- 肠道疾病
- 止血障碍
- 副蛋白血症
- 血液蛋白失调
- 肿瘤过程
- 肿瘤
- 淋巴瘤
- 综合症
- 骨髓增生异常综合征
- 原发性骨髓纤维化
- 多发性骨髓瘤
- 肿瘤,浆细胞
- 白血病
- 肿瘤转移
- 白血病前期
- 浆细胞瘤
- 肠道肿瘤
- 骨髓增生性疾病
- 骨髓增生异常-骨髓增生性疾病
- 移植物抗宿主病
- 癌前病变
- 药物的生理作用
- 药理作用的分子机制
- 抗感染药
- 核酸合成抑制剂
- 酶抑制剂
- 抗风湿药
- 抗代谢药、抗肿瘤药
- 抗代谢物
- 抗肿瘤药
- 免疫抑制剂
- 免疫因素
- 抗肿瘤药,烷基化
- 烷化剂
- 清髓性激动剂
- 抗肿瘤药,植物性
- 拓扑异构酶 II 抑制剂
- 拓扑异构酶抑制剂
- 皮肤病药物
- 抗菌剂
- 抗生素、抗肿瘤药
- 抗真菌剂
- 生殖控制剂
- 堕胎药,非甾体
- 堕胎剂
- 叶酸拮抗剂
- 神经钙蛋白抑制剂
- 环磷酰胺
- 依托泊甙
- 马法兰
- 氟达拉滨
- 磷酸氟达拉滨
- 甲氨蝶呤
- 他克莫司
- 西罗莫司
- 抗淋巴细胞血清
其他研究编号
- 06141
- P30CA033572 (美国 NIH 拨款/合同)
- CHNMC-06141
- CDR0000579340 (注册表标识符:NCI PDQ)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
anti-thymocyte globulin的临床试验
-
Hanyang University Seoul HospitalSeegene Medical Foundation完全的
-
Radboud University Medical CenterLeiden University Medical Center尚未招聘
-
University of Georgia招聘中消息曝光(顺序:Regular Then Flavor) | 消息曝光(顺序:Flavor Then Regular) | 无消息暴露(控制条件)美国